Dermatological Care of Gender-Diverse Patients in Australia

The document emphasizes the unique dermatological needs of transgender and gender-diverse (TGD) patients in Australia, particularly those undergoing gender-affirming treatments. It highlights potential skin, hair, and nail complications from treatments like puberty blockers and hormone therapies, including acne, xerosis, and patterned hair loss. The use of pharmacological interventions such as finasteride and dutasteride, and surgical options like hairline advancement and transplantation, are discussed for managing hair loss. Additionally, it addresses issues like hypertrichosis, hirsutism, and the impact of oestrogen on nail health. The document also covers risks associated with hormone therapy and surgeries, such as Systemic Lupus Erythematosus (SLE), intravaginal hair growth, and HPV infection, while stressing the importance of monitoring for skin cancer. It underscores the need for tailored care pathways and highlights financial and psychological barriers to accessing care, advocating for ongoing research and inclusivity in dermatological care for TGD individuals.